A Phase III trial for a first-in-class psoriasis drug provides encouraging data, but the emerging agents still have to prove their worth in a crowded autoimmune market.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Tse, M. IL-17 antibodies gain momentum. Nat Rev Drug Discov 12, 815–816 (2013). https://doi.org/10.1038/nrd4152
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4152
This article is cited by
-
Cyclization of peptides with two chemical bridges affords large scaffold diversities
Nature Chemistry (2018)